Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2016
Pharmacy Choice - News - Generic Drugs - May 30, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 41     Next >>     Go To Page:

5/30/16 - FLIXABI, Biogen's Infliximab Biosimilar Referencing Remicade, Approved in the European Union
FLIXABI was developed by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen. Earlier this year, Samsung Bioepis received approval for BENEPALI , a biosimilar referencing Enbrel ii. The approval of FLIXABI marks a major step forward for both Samsung Bioepis and Biogen.
5/30/16 - Israeli medical cannabis co to build New Mexico plant [Globes, Tel Aviv, Israel]
May 30 Israel generic drugs and medical devices company Panaxia has signed an agreement with Ultra Health, the leading medical cannabis distribution company in New Mexico, to build a cannabis processing plant. Panaxia said that the six-month pilot project would include a commitment to buying merchandise for $250,000. Ultra Health operates in five
5/29/16 - Changing default prescription settings in EMRs increased rates of generic drugs, Penn Medicine study finds
By a News Reporter-Staff News Editor at VerticalNews Health PHILADELPHIA Using generic instead of brand name medications can save money for both patients and health systems. A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania, found that a simple change to prescription default options in electronic
5/29/16 - Sun Pharma gets summons from U.S. Justice Department over drug prices [Big News Network (United Arab Emirates)]
WASHINGTON, U.S. U.S. Department of Justice has reportedly delivered summons to Sun Pharmaceutical Industries' U.S. wing to furnish the department with the prices and marketing of its generic drugs sold in the U.S.. It was added that the summons were in line with the U.S. investigation into generic drug pricing, jump started by Senator Bernie Sa
5/29/16 - Supply of standard generic medicine for cantonment general hospital [TendersInfo (India)]
Tenders are invited for Supply of standard generic medicine for cantonment general hospital, clement town dehradun for the year 2016-17 from C&F, Super distributor or authorized medical distributor of pharmaceutical companies FDR: Rs. 10,000/- Tender form cost: Rs. 500/-+ 13.5% VAT Last date: 22/06/2016 Major organization: CANTONMENT BOARD Address:
5/28/16 - Generics maker Sawai Pharma prepares to tap US market [Seven Days (United Arab Emirates)]
Sawai Pharmaceutical is gearing up to sell generic drugs in the U.S., carrying out a strategy shift that makes the huge American market a central pillar of the company's long-term growth plans. The U.S. generic-drug market is estimated at $91 billion, 10 times the annual market in Japan. The company intends to formulate pitavastatin and the three o
5/28/16 - Sun Pharma Q4 profit seen up 113%, Gleevec may drive US sales [tayyar.org (Lebanon)]
Drug major Sun Pharmaceutical Industries is expected to report strong earnings in January-March quarter with profit surging 112.6 percent to Rs 1,888.4 crore, according to average of estimates of analysts polled by CNBC-TV18. Revenue is seen rising 29 percent year-on-year to Rs 7,925.3 crore in Q4, driven by Gleevec generic drug sales that may be a
5/28/16 - Sun Pharma surges after US subsidiary posts strong FY 2016 results [Palestine Chronicle, The]
Sun Pharmaceutical Industries surged 4.57% to Rs 815.70 at 12:17 IST on BSE after the company's US subsidiary Taro Pharmaceutical Industries posted strong results for the financial year ended 31 March 2016. The stock hit a high of Rs 817.75 and a low of Rs 792 so far during the day. The stock had hit a 52- week high of Rs 1,003.65 on 27 May 2015.
5/28/16 - Xbrane Biopharma AB (publ) publicerar delrsrapport fr perioden januari - mars 2016 [Moj News Agency (Iran)]
Xbrane Biopharma genomfrde en nyemission som tillfrde bolaget 100,3 MSEK fre transaktionskostnader frdelat p 2 360 000 aktier och cirka 1 300 gare. Xbrane Biopharma tecknade avtal avseende frsljning och distribution av sin ledande Ranibizumab biosimilar, Xlucane, med det schweiziska biolkemedelsbolaget Helvetic Biopharma avseende den iranska...
5/27/16 - Coherus BioSciences Advances Differentiated IP Strategy for Humira Market Access [National News Agency (Lebanon)]
-Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus..
5/27/16 - Generic Injectables
The generic injectable drug segment is a rapidly evolving and highly competitive market that lacks a true data compass to assist decision makers in mapping strategies for success in this segment. Attempting to determine the optimal time to file an ANDA application is a process that can be worth significant profits for first-to-filers.
5/27/16 - Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
TORONTO, May 27, 2016 Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of 3,229,814 units of common shares and warrants, at
5/27/16 - Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants [Cihan News Agency (Turkey)]
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Intellipharmaceutics..
5/27/16 - Mylan Launches Generic Frova Tablets
By a News Reporter-Staff News Editor at Drug Week Mylan N.V. announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova Tablets. Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of approximately $88.3 million for the 12 months ending March 31, 2016, according to IMS Health. Currently, Mylan has 26
5/27/16 - Oncobiologics Announces Pricing of Its Initial Public Offering of Units
By a News Reporter-Staff News Editor at Drug Week Oncobiologics, Inc., a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, announced the pricing of its initial public offering of 5,833,334 units at a price to the public of $6.00 per unit.
5/26/16 - Coherus BioSciences Advances Differentiated IP Strategy for Humira Market Access
Coherus BioSciences, Inc., a leading pure-play, global biosimilars company with late-stage clinical products, today announced that the United States Patent and Trademark Office issued to Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880. These patents generally concern formulations of adalimumab, the active biological ingredient in Coherus
5/26/16 - Generic Pharmaceutical Vendor/Wholesaler [TendersInfo (India)]
Tenders are invited for Generic Pharmaceutical Vendor/Wholesaler SCOPE OF CONTRACT: This contract will be used as needed to purchase pharmaceuticals/over-the-counter and medically necessary items from responsive, responsible manufacturers/vendors/wholesalers. Any questions should be submitted in writing to designated contacts by close of...
5/26/16 - Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Intellipharmaceutics.
5/26/16 - JUBILANT LIFE GETS NOD FOR SODIUM CHLORIDE INJECTION
Jubilant HollisterStier LLC, the US subsidiary of Jubilant Life Sciences, has got approval from the US Food and Drug Administration for its abbreviated new drug application for 0.9 percent sodium chloride injection USP, 3 ml and 10 ml vials. The injections are used for diluting or dissolving drugs for IV, IM or subcutaneous injections. The company'
5/26/16 - United States : IFC Invests $30 Mln in Ascendis Health to Promote Access to High-Quality Pharmaceuticals In Emerging Markets [TendersInfo (India)]
IFC, a member of the World Bank Group, will invest up to $30 million in Ascendis Health Limited, a South Africa- based, Johannesburg Stock Exchange listed emerging global leader in life sciences, wellness and nutrition products, to promote access to affordable generic pharmaceuticals and medical products in developing countries. Remedica is a major
5/25/16 - Drug Costs Up in 2013/14 for Canadian Public Drug Plans Due to Increased Spending on High-Cost Drugs; Reduced Savings From Generics
Patented Medicine Prices Review Board. The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, today published the second edition of CompassRx, its flagship annual report that monitors major developments in drug pricing and reimbursement in Canada, analyzes trends, and...
5/25/16 - IFC Invests $30 Mln in Ascendis Health to Promote Access to High-Quality Pharmaceuticals In Emerging Markets
Release date- 24052016- IFC, a member of the World Bank Group, will invest up to $30 million in Ascendis Health Limited, a South Africa- based, Johannesburg Stock Exchange listed emerging global leader in life sciences, wellness and nutrition products, to promote access to affordable generic pharmaceuticals and medical products in developing countr
5/25/16 - Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, joins GPhA Board
Release date- 24052016- London- Hikma Pharmaceuticals PLC,, the fast growing multinational pharmaceutical group, today announces that Michael Raya, Chief Executive Officer of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, will join the Board of Directors of the Generic Pharmaceutical Association. Hikma operates through three.
5/25/16 - Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Release date- 24052016- Holzkirchen- Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche's EU-licensed MabThera. Sandoz is seeking approval for the same indications as the reference product.
5/24/16 - Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
Allergan plc today announced that the New Drug Application filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema associated with rosacea in adults, has been accepted by the U.S. Allergan expects the Prescription Drug User Fee Act date to be in the first half of 201
Articles(s): 1 - 25 of 41     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415